search
Back to results

Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS

Primary Purpose

Premenstrual Syndrome, Mastodynia

Status
Terminated
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
20mg VAC BNO 1095 FCT
Placebo
Sponsored by
Bionorica SE
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Premenstrual Syndrome focused on measuring vitex agnus castus, clinical trial, cyclic mastodynia, PMS, prospective

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Females 18 to 45 Y with a history of cyclic mastodynia and PMS
  • Stable cycle duration of 25 to 35 days.
  • Subject is reporting at least one moderate or severe physical PMS symptom moderate and one psychic symptom, using the COPE symptom list
  • Subject is reporting symptoms of a total score of at least 15 in the late luteal phase of the preceding cycle, using the COPE symptom list
  • In both run-in cycles: Confirmation of cyclic mastodynia based on daily recordings of patient diary (VAS and COPE data)
  • Subject provides a negative pregnancy test at study start and is willing to use a hormone-free medically acknowledged contraception methods with a PEARL-index < 1 % from enrolment
  • Unsuspicious breast USG/mammogram not older than 12 months ruling out signs of malignancy

Exclusion Criteria:

  • Hypersensitivity to the active substance or to the excipients of the IMP
  • Proof of PMDD according to DSM IV criteria as defined by APA

  • Intake of any of the following medications before treatment start and within 6 months prior to screening visit:

    • hypothalamic hormones
    • injectable contraceptives: 3-month injection

  • Intake of any of the following medications (including herbal or homeopathic drugs) before treatment start and within 3 months prior to screening visit:

    • any treatment for mastodynia or premenstrual complaints
    • sexual hormones, combinations and inhibitors
    • pituitary hormones and their inhibitors
    • dopamine-agonists and dopamine-antagonists
    • neuroleptics, antidepressants (including serotonin- and serotonin-norepinephrine-reuptake-inhibitors)
    • prolactin-inhibitors or prolactin stimulating preparations
    • drug abuse or continuous intake of NSAIDs or any other analgetics including antirheumatics (up to 2 tablets of paracetamol 500 mg or equivalent per week are allowed)
    • spironolactone
    • gonadotrophin inhibitors
    • diuretics
    • danazol
    • psychotropic agents
  • Any psychiatric treatment before treatment start and within 12 months prior to screening visit

  • Medical history or presence of any of the following medical conditions/ diseases before treatment start:

    • Uncontrolled diabetes mellitus: Patients with known diabetes mellitus, who have a glycosylated haemoglobin (HbA1c) ≥ 7% as assessed at visit S-1
    • Uncontrolled hypertension: Patients with a diastolic blood pressure >90mmHg at visit S-2
    • Known cardiac insufficiency, coronary heart disease, valvular heart disease, cardiac arrhythmia, QT interval prolongation or other severe cardiac disease at visit S-2
    • Known clinically significant organ or systemic diseases or any other relevant medical condition such that in the opinion of the investigator, the significance of the disease or condition will compromise the subject's participation in the study
    • Known hyperprolactinemia (serum prolactin basal > 50 ng/ml or > 1050 mlU/L)
    • Known hypo-/hyperthyreosis
    • Known hypo-/hyperparathyroidism
    • Known pituitary tumor including prolactinoma
    • Known chronic kidney disease

    • Known gastrointestinal, or liver diseases, such as:

      i. active peptic gastric ulcer ii. malabsorption iii. hepatitis

    • endometriosis
    • breast cancer, fibroadenoma, intraductal papilloma or other malignancy within the last 10 years
    • suspicious non-verified finding on any breast ultrasound or mammograms in the past
    • galactorrhea of degree II or III
    • purulent or bloody nipple discharge
    • refractory and/or unverified breast skin- or nipple/areola lesions
    • pregnancy, lactation
    • wish for pregnancy
    • any surgery planned to take place during the trial including breast cyst puncture
  • Values of safety laboratory parameters outside normal ranges and clinically relevant as assessed by the investigator at S-1
  • At screening:TSH > 2.5 mU/L
  • Patients who have difficulties in understanding the language in which the patient information is given
  • Patients who are members of the staff of the study centre, staff of the sponsor or CRO, the investigator herself or close relatives of the investigator

Sites / Locations

  • Private Doctor's office - Dr. Hannes Herold

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

VAC BNO 1095 2x10 mg FCT

Placebo

Arm Description

VAC BNO 1095 2x10 mg FCT 2 tablets of verum in the morning, oral, 3 months treatment

2 tablets in the morning, oral, 3 months treatment

Outcomes

Primary Outcome Measures

Maximum severity of cyclic breast pain
Maximum severity of cyclic breast pain after 3 months treatment under Investigational Medicinal Product (IMP). The severity of cyclic breast pain will be self-assessed by the patient on a Visual Analogue Scale (VAS).

Secondary Outcome Measures

Severity of cyclic breast pain and PMS symptoms
Maximum severity of cyclic breast pain after 1 and 2 months treatment, respectively. The severity of cyclic breast pain will be self-assessed by the patient on a VAS Average severity of cyclic mastodynia, determined in the late luteal phase of each of the treatment cycles. Intensity of PMS assessed by means of a PMS diary (COPE = calendar of premenstrual experiences) during each of the treatment cycles Overall assessments of efficacy on cyclic mastodynia and PMS by patient and investigator at study end by a score ranging from 1 to 5 Subgroup analysis: A. Patients with the waist circumference ≤ 90 cm B. Patients with the waist circumference > 90 cm. For both subgroups A. and B.: Maximum severity of cyclic breast pain after 3 months treatment under IMP. The severity of cyclic breast pain will be self-assessed by the patient on a VAS.

Full Information

First Posted
May 16, 2013
Last Updated
September 12, 2016
Sponsor
Bionorica SE
search

1. Study Identification

Unique Protocol Identification Number
NCT01870687
Brief Title
Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS
Official Title
Prospective, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Randomized Clinical Trial to Proof Efficacy and Safety of 20 mg (2 Tablets of 10 mg) VAC BNO 1095 FCT in Patients Suffering From Cyclic Mastodynia and PMS
Study Type
Interventional

2. Study Status

Record Verification Date
September 2016
Overall Recruitment Status
Terminated
Study Start Date
June 2013 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
October 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bionorica SE

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to proof the efficacy and safety of 20 mg (2 tablets of 10 mg) VAC BNO 1095 film-coated tablets in patients suffering from cyclic mastodynia and PMS (pre menstrual syndrome).
Detailed Description
The study consists of a 2-cycle run-in period, followed by 3 cycles of treatment. After first screening at S-2 further visits are scheduled after the end of each of the first and second run-in cycle, and after the first, second and third treatment cycle, respectively. At least 220 patients should be eligible for randomisation, 110 to each treatment group, of which 160 (80 per group) will be available for data evaluation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premenstrual Syndrome, Mastodynia
Keywords
vitex agnus castus, clinical trial, cyclic mastodynia, PMS, prospective

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
96 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VAC BNO 1095 2x10 mg FCT
Arm Type
Experimental
Arm Description
VAC BNO 1095 2x10 mg FCT 2 tablets of verum in the morning, oral, 3 months treatment
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
2 tablets in the morning, oral, 3 months treatment
Intervention Type
Drug
Intervention Name(s)
20mg VAC BNO 1095 FCT
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Maximum severity of cyclic breast pain
Description
Maximum severity of cyclic breast pain after 3 months treatment under Investigational Medicinal Product (IMP). The severity of cyclic breast pain will be self-assessed by the patient on a Visual Analogue Scale (VAS).
Time Frame
after 3 months treatment under Investigational Medicinal Product (IMP).
Secondary Outcome Measure Information:
Title
Severity of cyclic breast pain and PMS symptoms
Description
Maximum severity of cyclic breast pain after 1 and 2 months treatment, respectively. The severity of cyclic breast pain will be self-assessed by the patient on a VAS Average severity of cyclic mastodynia, determined in the late luteal phase of each of the treatment cycles. Intensity of PMS assessed by means of a PMS diary (COPE = calendar of premenstrual experiences) during each of the treatment cycles Overall assessments of efficacy on cyclic mastodynia and PMS by patient and investigator at study end by a score ranging from 1 to 5 Subgroup analysis: A. Patients with the waist circumference ≤ 90 cm B. Patients with the waist circumference > 90 cm. For both subgroups A. and B.: Maximum severity of cyclic breast pain after 3 months treatment under IMP. The severity of cyclic breast pain will be self-assessed by the patient on a VAS.
Time Frame
After 1, 2 and 3 months of treatment

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Females 18 to 45 Y with a history of cyclic mastodynia and PMS Stable cycle duration of 25 to 35 days. Subject is reporting at least one moderate or severe physical PMS symptom moderate and one psychic symptom, using the COPE symptom list Subject is reporting symptoms of a total score of at least 15 in the late luteal phase of the preceding cycle, using the COPE symptom list In both run-in cycles: Confirmation of cyclic mastodynia based on daily recordings of patient diary (VAS and COPE data) Subject provides a negative pregnancy test at study start and is willing to use a hormone-free medically acknowledged contraception methods with a PEARL-index < 1 % from enrolment Unsuspicious breast USG/mammogram not older than 12 months ruling out signs of malignancy Exclusion Criteria: Hypersensitivity to the active substance or to the excipients of the IMP Proof of PMDD according to DSM IV criteria as defined by APA Intake of any of the following medications before treatment start and within 6 months prior to screening visit: hypothalamic hormones injectable contraceptives: 3-month injection Intake of any of the following medications (including herbal or homeopathic drugs) before treatment start and within 3 months prior to screening visit: any treatment for mastodynia or premenstrual complaints sexual hormones, combinations and inhibitors pituitary hormones and their inhibitors dopamine-agonists and dopamine-antagonists neuroleptics, antidepressants (including serotonin- and serotonin-norepinephrine-reuptake-inhibitors) prolactin-inhibitors or prolactin stimulating preparations drug abuse or continuous intake of NSAIDs or any other analgetics including antirheumatics (up to 2 tablets of paracetamol 500 mg or equivalent per week are allowed) spironolactone gonadotrophin inhibitors diuretics danazol psychotropic agents Any psychiatric treatment before treatment start and within 12 months prior to screening visit Medical history or presence of any of the following medical conditions/ diseases before treatment start: Uncontrolled diabetes mellitus: Patients with known diabetes mellitus, who have a glycosylated haemoglobin (HbA1c) ≥ 7% as assessed at visit S-1 Uncontrolled hypertension: Patients with a diastolic blood pressure >90mmHg at visit S-2 Known cardiac insufficiency, coronary heart disease, valvular heart disease, cardiac arrhythmia, QT interval prolongation or other severe cardiac disease at visit S-2 Known clinically significant organ or systemic diseases or any other relevant medical condition such that in the opinion of the investigator, the significance of the disease or condition will compromise the subject's participation in the study Known hyperprolactinemia (serum prolactin basal > 50 ng/ml or > 1050 mlU/L) Known hypo-/hyperthyreosis Known hypo-/hyperparathyroidism Known pituitary tumor including prolactinoma Known chronic kidney disease Known gastrointestinal, or liver diseases, such as: i. active peptic gastric ulcer ii. malabsorption iii. hepatitis endometriosis breast cancer, fibroadenoma, intraductal papilloma or other malignancy within the last 10 years suspicious non-verified finding on any breast ultrasound or mammograms in the past galactorrhea of degree II or III purulent or bloody nipple discharge refractory and/or unverified breast skin- or nipple/areola lesions pregnancy, lactation wish for pregnancy any surgery planned to take place during the trial including breast cyst puncture Values of safety laboratory parameters outside normal ranges and clinically relevant as assessed by the investigator at S-1 At screening:TSH > 2.5 mU/L Patients who have difficulties in understanding the language in which the patient information is given Patients who are members of the staff of the study centre, staff of the sponsor or CRO, the investigator herself or close relatives of the investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrzej Witek, MD PhD Prof.
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Hannes Herold, Dr. med.
Official's Role
Study Chair
Facility Information:
Facility Name
Private Doctor's office - Dr. Hannes Herold
City
Munich
State/Province
Bavaria
ZIP/Postal Code
80802
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS

We'll reach out to this number within 24 hrs